Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1023-1038 , December 2008

Receptor tyrosine kinase inhibitors in thyroid cancer

  • Massimo Santoro, MD, PhD (Professor of Pathology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39-081-7463056; Fax: +39-081-7463037.

References 

  1. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003;300:949
  2. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–158
  3. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Reviews. Cancer. 2004;4:718–727
  4. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006;312:1175–1178
  5. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature. 2006;441:457–462
  6. Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology & Metabolism. 2006;2:42–52
  7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer. 2006;6:292–306
  8. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113
  9. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America. 2008;37:375–387
  10. Pacifico F, Mauro C, Barone C, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. The Journal of Biological Chemistry. 2004;279:54610–54619
  11. Ludwig L, Kessler H, Wagner M, et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Research. 2001;61:4526–4535
  12. Palona I, Namba H, Mitsutake N, et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 2006;147:5699–5707
  13. Mitsiades CS, McMillin D, Kotoula V, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4013–4021
  14. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043
  15. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287–290
  16. Frank-Raue K, Fabel M, Delorme S, et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. European Journal of Endocrinology. 2007;157:215–220
  17. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2007;92:3466–3469
  18. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer. 2006;13:535–540
  19. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–323
  20. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology. 2008;(Epub ahead of print)
  21. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of Sorafenib in advanced thyroid cancer. Journal of Clinical Oncology. 2008;(Epub ahead of print)
  22. Hong D, Ye L, Gagel R, et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Molecular Cancer Therapeutics. 2008;7:1001–1006
  23. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. The New England Journal of Medicine. 2008;359:31–42
  24. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. Journal of Clinical Oncology. 2007;ASCO Annual Meeting Proceedings. Vol. 25 (June 20 Supplement): Abstract No: 6018
  25. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology. 2008;ASCO Annual Meeting Proceedings Vol. 26 (May 20 Supplement): Abstract No: 6025
  26. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Annals of Internal Medicine. 2008;148:567
  27. Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anti-cancer Drugs. 2008;19:547–552
  28. Salgia R, Sherman S, Hong DS, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Journal of Clinical Oncology. 2008;ASCO Annual Meeting Proceedings. Vol. 26 (May 20 supplement): Abstract No: 3522
  29. Schlumberger M, Carlomagno F, Baudin E, et al. New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice. Endocrinology & Metabolism. 2008;4:22–32
  30. Drosten M, Hilken G, Böckmann M, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Journal of the National Cancer Institute. 2004;96:1231–1239
  31. de Martimprey H, Bertrand JR, Fusco A, et al. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research. 2008;36:e2
  32. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Research. 1996;56:2167–2170
  33. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3603–3610
  34. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research. 2002;62:7284–7290
  35. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4070–4076
  36. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. Jouranl of National Cancer Institute. 2006;98:326–334
  37. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research. 2006;66:8715–8721
  38. Knowles PP, Murray-Rust J, Kjaer S, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. The Journal of Biological Chemistry. 2006;281:33577–33587
  39. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Letters. 2006;232:90–98
  40. Gimm O, Dziema H, Brown J, et al. Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. International Journal of Cancer. 2001;92:70–74
  41. McGregor LM, McCune BK, Graff JR, et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:4540–4545
  42. Strock CJ, Park JI, Rosen DM, et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2006;91:79–84
  43. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews. Drug Discovery. 2008;7:504–516
  44. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene. 1992;7:2549–2553
  45. Mineo R, Costantino A, Frasca F, et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology. 2004;145:4355–4365
  46. Fujarewicz K, Jarzab M, Eszlinger M, et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine-Related Cancer. 2007;14:809–826
  47. Griffith OL, Melck A, Jones SJ, et al. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology. 2006;24:5043–5051
  48. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–6656
  49. Nardone HC, Ziober AF, LiVolsi VA, et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer. 2003;98:1386–1393
  50. Papotti M, Olivero M, Volante M, et al. Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocrine Pathology. 2000;11:19–30
  51. Liu Z, Hou P, Ji M, et al. Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and PI3K/Akt and MAP Kinase Pathways in Anaplastic and Follicular Thyroid Cancers. The Journal of Clinical Endocrinology and Metabolism. 2008;(Epub ahead of print)
  52. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. The American Journal of Surgical Pathology. 2005;29:544–549
  53. Dremier S, Taton M, Coulonval K, et al. Mitogenic, dedifferentiating, and scattering effects of hepatocyte growth factor on dog thyroid cells. Endocrinology. 1994;135:135–140
  54. Wang MH, Lee W, Luo YL, et al. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. The Journal of Pathology. 2007;213:402–411
  55. Chattopadhyay C, El-Naggar AK, Williams MD, et al. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head & Neck. 2008;30:991–1000
  56. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology. 2001;2:127–137
  57. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. The New England Journal of Medicine. 2008;358:1160–1174
  58. Elliott DD, Sherman SI, Busaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology. 2008;39:15–20
  59. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3662–3666
  60. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clinical Cancer Research. 2004;10:8594–8602
  61. Haugen DR, Akslen LA, Varhaug JE, et al. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1996;56:1184–1188
  62. Wiseman SM, Melck A, Masoudi H, et al. Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis. Annals of Surgical Oncology. 2008;(Epub ahead of print)
  63. Delys L, Detours V, Franc B, et al. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene. 2007;26:7894–7903
  64. Haugen DR, Akslen LA, Varhaug JE, et al. Expression of c-erbB-2 protein in papillary thyroid carcinomas. British Journal of Cancer. 1992;65:832–837
  65. Hébrant A, van Staveren WC, Delys L, et al. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Experimental Cell Research. 2007;313:3276–3284
  66. Croyle M, Akeno N, Knauf JA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research. 2008;68:4183–4191
  67. Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. British Journal of Cancer. 2005;92:1110–1116
  68. Younes MN, Yigitbasi OG, Park YW, et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Research. 2005;65:4716–4727
  69. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Molecular Cancer Therapeutics. 2005;4:632–640
  70. Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31:105–113
  71. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2341–2347
  72. Eggo MC, Hopkins JM, Franklyn JA, et al. Expression of fibroblast growth factors in thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 1995;80:1006–1011
  73. de la Torre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocrine-Related Cancer. 2006;13:931–944
  74. St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146:1145–1153
  75. Kondo T, Zheng L, Liu W, et al. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Research. 2007;67:5461–5470
  76. Ezzat S, Huang P, Dackiw A, et al. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research. 2005;11:1336–1341
  77. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003;22:6589–6597
  78. Wang Z, Chakravarty G, Kim S, et al. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clinical Cancer Research. 2006;12:4755–4765
  79. Coulonval K, Vandeput F, Stein RC, et al. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. The Biochemical Journal. 2000;348:351–358
  80. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221–230
  81. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews. Cancer. 2008;8:579–591
  82. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews. Cancer. 2008;8:592–603
  83. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008 Jun 25;(Epub ahead of print)
  84. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995;11:1569–1579
  85. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. The American Journal of Pathology. 1999;155:1967–1976
  86. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. The Journal of Clinical Endocrinology and Metabolism. 1997;82:3741–3747
  87. Tuttle RM, Fleisher M, Francis GL, et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1737–1742
  88. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2001;86:656–658
  89. Huang SM, Lee JC, Wu TJ, et al. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World Journal of Surgery. 2001;25:302–306
  90. Yu XM, Lo CY, Chan WF, et al. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clinical Cancer Research. 2005;11:8063–8069
  91. Hung CJ, Ginzinger DG, Zarnegar R, et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3694–3699
  92. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, et al. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clinical Cancer Research. 2007;13:4519–4527
  93. Schoenberger J, Grimm D, Kossmehl P, et al. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology. 2004;145:1031–1038
  94. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 2000;128:1059–1065
  95. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes & Development. 2008;22:1276–1312
  96. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nature Reviews. Cancer. 2004;4:806–813
  97. Heldin NE, Gustavsson B, Claesson-Welsh L, et al. Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proceeding of the National Academy of Sciences of the United States of America. 1988;85:9302–9306
  98. Dziba JM, Ain KB. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2127–2135
  99. de Groot JW, Plaza Menacho I, Schepers H, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006;139:806–814

PII: S1521-690X(08)00109-7

doi: 10.1016/j.beem.2008.09.012

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1023-1038 , December 2008

Article Tools

* Image Usage & Resolution